Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC–ESI–MS/MS: Application to Pharmacokinetic Study in Mice

Abhishek Dixit; Sadanand Rangnathrao Mallurwar; Suresh P Sulochana; Mohd Zainuddin; Ramesh Mullangi

doi:10.1055/a-0677-3066

Drug Research, Table of Contents

Drug Res (Stuttg) 2019; 69(06): 330-336
DOI: 10.1055/a-0677-3066

Original Article

Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC–ESI–MS/MS: Application to Pharmacokinetic Study in Mice

Authors

Abhishek Dixit

¹Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
Sadanand Rangnathrao Mallurwar

¹Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
Suresh P Sulochana

¹Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
Mohd Zainuddin

¹Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India
Ramesh Mullangi

¹Drug Metabolism and Pharmacokinetics, Jubilant Biosys, Yeshwanthpur, Bangalore, India

Abstract

A simple, sensitive and rapid assay method has been developed and validated as per regulatory guideline for the estimation of tofacitinib on mice dried blood spots (DBS) using liquid chromatography coupled to tandem mass spectrometry with electro spray ionization in the positive-ion mode. The method employs liquid extraction of tofacitinib from DBS disk of mice whole blood followed by chromatographic separation using 5 mM ammonium acetate (pH 6.5):acetonitrile (20:80, v/v) at a flow rate of 0.60 mL/min on an X-Terra Phenyl column with a total run time 2.5 min. The MS/MS ion transitions monitored were m/z 313→149 for tofacitinib and m/z 316→149 for the internal standard (¹³C_3, ¹⁵N-tofacitinib). The assay was linear in the range of 0.99–1980 ng/mL. The intra- and inter-day precision was in the range of 1.17–10.3 and 3.37–10.9%, respectively. Stability studies showed that tofacitinib was stable on DBS cards for one month. This novel method has been applied to analyze the DBS samples of tofacitinib obtained from a pharmacokinetic study in mice.

Key words

Tofacitinib - dried blood spot - LC-MS/MS - method validation - mice - pharmacokinetics

Full Text

References

References
1 Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritis: Pathogenic or protective?. Arthritis Rheum 2003; 48: 2092-2096
2 Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005; 32: 1650-1653
3 Meyer DM, Jesson MI, Li X. et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm 2010; 7: 41
4 Milici AJ, Kudlacz EM, Audoly L. et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008; 10: R14
5 LaBranche TP, Jesson MI, Radi ZA. et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012; 64: 3531-3542
6 Ghoreschi K, Jesson MI, Li X. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186: 4234-4243
7 Lee EB, Fleischmann R, Hall S. et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naive patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: S1049
8 van Vollenhoven RF, Fleischmann R, Cohen S. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519
9 Fleischmann R, Kremer J, Cush J. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507
10 Kremer J, Li ZG, Hall S. et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Intern Med 2013; 159: 253-261
11 Burmester GR, Blanco R, Charles-Schoeman C. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 2013; 381: 451-460
12 van der Heijde D, Tanaka Y, Fleischmann R. et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-570
13 Paniagua R, Campbell A, Changelian PS. et al. Quantitative analysis of the immunosuppressant CP-690,550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection. Ther Drug Monit 2005; 27: 608-616
14 Dowty ME, Lin J, Ryder TF. et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos 2014; 42: 759-773
15 Sharma K, Giri K, Dhiman V. et al. A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: Application to a pharmacokinetic study. Biomed Chromatogr 2015; 29: 722-732
16 Kadi AA, Abdelhameed AS, Darwish HW. et al. Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine. Trop J Pharm Res 2016; 15: 2683-2692
17 Abdelhameed AS, Attwa MW, Kadi AA. An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma. Biomed Chromatogr 2017; 31: e3793
18 US DHHS, FDA, CDER, CVM, Guidance for Industry: Bioanalytical method validation. U.S. department of health and human services, food and drug administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). 2018. Rockville, MD, USA.:
19 Freeman JD, Rosman LM, Ratcliff JD. et al. State of the science in dried blood spots. Clin Chem 2018; 64: 656-679
20 Demirev PA. Dried blood spots: analysis and applications. Anal Chem 2013; 85: 779-789